Peripheral Neuropathy from Docetaxel and Cisplatin Chemotherapy
Author Information
Author(s): PHE Hilkens, LC Pronk, J Verweij, CJ Vecht, WJL van Putten, MJ van den Bent
Primary Institution: Dr Daniel den Hoed Cancer Center and University Hospital, Rotterdam, The Netherlands
Hypothesis
Does the combination of docetaxel and cisplatin induce peripheral neuropathy in patients undergoing chemotherapy?
Conclusion
The combination of docetaxel and cisplatin leads to a significant incidence of sensory neuropathy in patients.
Supporting Evidence
- 53% of evaluable patients developed sensory neuropathy.
- 74% of patients receiving cumulative doses above 200 mg/m2 experienced neuropathy.
- Neuropathy severity was graded as mild in 15, moderate in 10, and severe in 1 patient.
Takeaway
When patients take two specific cancer drugs together, many of them can feel numbness or tingling in their hands and feet.
Methodology
A dose-escalating study was conducted with 63 patients, assessing neuropathy through clinical evaluations and vibration perception threshold measurements.
Limitations
The study did not include a comparative trial with single agents, making it difficult to determine the specific contributions of each drug to neuropathy.
Participant Demographics
Patients aged 18-75 with metastatic or locally advanced solid tumors, excluding those with pre-existing neuropathy.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website